CARe To Understand What Will Shape CAR T’s Future?
Executive Summary
Three ‘C’ factors are impacting CAR T-cell therapies now: COVID-19, China and Commercialization. With logistical, reimbursement and pricing hurdles complicating the landscape, what is ahead for this space with fast innovation and roaring competition?
When little to no treatment options were left for refractory patients, early CAR T data in R/R ALL raised hopes of extending young patients’ life expectancy, with Kymriah® heralding an exciting new era in hematological cancers treatment.
- Kymriah® was joined by Yescarta® in DLBCL to become the first CAR Ts to win landmark FDA approval in 2017
- Yescarta’s benefits in DLBCL are significant, though as yet less impressive than Kymriah’s in R/R ALL, demonstrating that outcomes across cancer types won’t be equal
Kymriah® and Yescarta® have opened new doors for developers of cellular immunotherapies who are expanding their focus to other hematological cancers, plus providing new/additional options for currently addressed lymphomas.
Description
This white paper aims to give an overview of where CAR T is now and how Market Access and R&D events are likely to shape the near future, with news from China and intelligence gathered from discussions with CAR T physicians and commercial players. The CAR T market now:
- COVID cuts into Yescarta® uptake
- Confounding US CAR T reimbursement dynamics
- EU reimbursement disparity
- Wider COVID-19 implications for CAR T’s
- China ups the pace of its CAR T race
- The road ahead for CAR T